Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Initial clinical studies of piritrexim.

J Laszlo1, W D Brenckman, E Morgan

  • 1Duke Medical Center, Durham, NC.

NCI Monographs : a Publication of the National Cancer Institute
|January 1, 1987
PubMed
Summary

Piritrexim (PTX), a dihydrofolate reductase inhibitor, shows promise in early cancer trials. Dose-limiting toxicities are mainly hematologic, with manageable side effects for both intravenous and oral administration.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Probing lepton flavour violation via neutrinoless [Formula: see text] decays with the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

A new method to distinguish hadronically decaying boosted <i>Z</i> bosons from <i>W</i> bosons using the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

Search for supersymmetry at [Formula: see text] TeV in final states with jets and two same-sign leptons or three leptons with the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

Measurement of the differential cross-sections of prompt and non-prompt production of [Formula: see text] and [Formula: see text] in <i>pp</i> collisions at [Formula: see text] and 8 TeV with the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

Measurement of the transverse momentum and [Formula: see text] distributions of Drell-Yan lepton pairs in proton-proton collisions at [Formula: see text] TeV with the ATLAS detector.

The European physical journal. C, Particles and fields·2017
Same author

Muon reconstruction performance of the ATLAS detector in proton-proton collision data at [Formula: see text]=13 TeV.

The European physical journal. C, Particles and fields·2017

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Piritrexim (PTX) is a novel, lipid-soluble dihydrofolate reductase (DHFR) inhibitor.
  • DHFR is a critical enzyme in folate metabolism, essential for DNA synthesis and cell proliferation.

Purpose of the Study:

  • To evaluate the safety and tolerability of piritrexim (PTX) in initial Phase I clinical trials.
  • To determine the maximum tolerated dose (MTD) for both intravenous (IV) and oral administration of PTX.

Main Methods:

  • Phase I clinical trials involving daily administration of PTX for 5 days in cancer patients.
  • Assessment of dose-limiting toxicities, including hematologic, phlebitis, and gastrointestinal effects.
  • Determination of MTD for IV and oral PTX routes.

Related Experiment Videos

Main Results:

  • The primary dose-limiting toxicities were hematologic, including leukopenia, granulocytopenia, and thrombocytopenia.
  • Phlebitis was observed with IV administration, and nausea/vomiting with oral administration.
  • The MTD for IV PTX was 170 mg/m2/day and for oral PTX was 480 mg/m2/day, both for 5 days.

Conclusions:

  • Piritrexim demonstrates a manageable toxicity profile in early-phase cancer studies.
  • Oral administration of PTX may benefit from divided daily dosing to reduce gastrointestinal toxicity.
  • Unlike earlier folate antagonists, PTX did not induce neurologic or histamine-like adverse events.